Androgen receptor variation affects prostate cancer progression and drug resistance

Edel McCrea, Tristan M. Sissung, Douglas K. Price, Cindy H. Chau, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Significant therapeutic progress has been made in treating prostate cancer in recent years. Drugs such as enzalutamide, abiraterone, and cabazitaxel have expanded the treatment armamentarium, although it is not completely clear which of these drugs are the most-effective option for individual patients. Moreover, such advances have been tempered by the development of therapeutic resistance. The purpose of this review is to summarize the current literature pertaining to the biochemical effects of AR variants and their consequences on prostate cancer therapies at both the molecular level and in clinical treatment. We address how these AR splice variants and mutations affect tumor progression and therapeutic resistance and discuss potential novel therapeutic strategies under development. It is hoped that these therapies can be administered with increasing precision as tumor genotyping methods become more sophisticated, thereby lending clinicians a better understanding of the underlying biology of prostate tumors in individual patients.

Original languageEnglish
Pages (from-to)152-162
Number of pages11
JournalPharmacological Research
StatePublished - 1 Dec 2016
Externally publishedYes


  • AR-V7
  • Androgen receptor
  • Mutation
  • Pharmacology
  • Prostate cancer


Dive into the research topics of 'Androgen receptor variation affects prostate cancer progression and drug resistance'. Together they form a unique fingerprint.

Cite this